Notice2023-20323
National Institute on Drug Abuse; Notice of Closed Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 20, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 181 (Wednesday, September 20, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 181 (Wednesday, September 20, 2023)]
[Notices]
[Page 64919]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-20323]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Board of Scientific
Counselors, NIDA.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in sections 552b(c)(6), title
5 U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute on Drug Abuse, including consideration of personnel
qualifications and performance, and the competence of individual
investigators, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, NIDA.
Date: October 24, 2023.
Time: 8:30 a.m. to 5:40 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: National Institute on Drug Abuse, NIH, Biomedical
Research Center, 251 Bayview Boulevard, Baltimore, MD 21224 (Virtual
Meeting).
Date: October 25, 2023.
Time: 9:00 a.m. to 3:10 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: National Institute on Drug Abuse, NIH, Biomedical
Research Center, 251 Bayview Boulevard, Baltimore, MD 21224 (Virtual
Meeting).
Contact Person: Megan E. Bollinger, Ph.D., Management Analyst,
Office of the Scientific Director, National Institute on Drug Abuse,
Biomedical Research Center, 251 Bayview Boulevard, Suite 200,
Baltimore, MD 21224, (443) 740-2466, <a href="/cdn-cgi/l/email-protection#84e9e1e3e5eaaae6ebe8e8edeae3e1f6c4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="eb868e8c8a85c58984878782858c8e99ab858283c58c849d">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 14, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20323 Filed 9-19-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 20, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.